Systemic: Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia and glycosuria. This is more likely to occur with occlusive dressings and with the more potent steroids. Patients with liver failure or children may be at higher risk. Lightheadedness and hives have been reported rarely. Following prolonged application around the eyes, cataracts, and glaucoma may develop. In diffusely atrophied skin, blood vessels may become visible on the skin surface.
View ADR Monitoring Form